Somaxon - Silenor

The company: Somaxon
The drug: Silenor
The target: Insomnia
Sales: $2.1 million for Q3

By the time Somaxon ($SOMX) won FDA approval for its insomnia drug Silenor on the third try back in the spring of 2010, the lengthy, frustrating process had already bled the company of $170 million. But an approval would do nothing to help the biotech find a big partner to market the drug. Instead, it started a sales effort with a tiny marketing force, which hit the streets with a new product in an already heavily crowded field.

Somaxon had found a recipe for disaster. By late last year, the San Diego-based company was forced to ax a large portion of its headquarters staff. And Stifel Nicolaus Weisel was hired as a strategic adviser to plumb the potential for a sale for a company with only $3.7 million in third-quarter (2011) sales.

But Somaxon's fortunes continued to worsen. By the third quarter of this year, product sales had slipped to a bit more than $2 million, lunch money in the pharma business.

Somaxon has inked a couple of small development deals in South Korea and Canada. And there's an OTC version to consider when looking at its U.S. potential. But this is one company that found itself in the wrong place at the wrong time with the wrong product.

For more:
Somaxon to axe HQ staffers as adviser explores possible sale
Somaxon buoyed by FDA word on OTC Silenor
Somaxon (finally) wins FDA approval for sleep drug Silenor

 

 

Somaxon - Silenor
Read more on

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.